摘要
目的分析血清肿瘤标志物谱及趋化因子蛋白在肺癌中的表达及预测价值。方法选取肺癌患者(观察组)150例及同期入院健康体检者(对照组)150例,采用化学发光微粒子免疫检测法测定胃泌素释放肽前体(ProGRP)、癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)及细胞角蛋白19片段(Cyfra21-1)4种肿瘤标志物水平,采用多重细胞因子免疫检测方法完成趋化因子蛋白的测定。结果观察组ProGRP、CEA、SCC及Cyfra21-1 4种肿瘤标志物水平显著高于对照组(P<0.05);观察组LIF、LIGHT、GRO水平高于对照组(P<0.05);观察组CCL28、NAP-2及MDC水平低于对照组(P<0.05)。结论非小细胞肺癌患者定期测定血清肿瘤标志物谱及趋化因子蛋白能预测治疗预后,评估临床疗效。
Objective To analyze the expression and predictive value of serum tumor markers spectrum and chemokine pro- tein in lung cancer and predictive value. Methods One hundred anti fifty patients with lung cancer were selected as the observation group and contemporaneous 150 individuals undergoing physical examination served the control group. The levels of ProGRP,CEA, SCC and Cyfra21-1 were measured by chemiluminescence microparticle immunoassay. The chemokine protein was determined by multiple immunofluorescent assay. Results The levels of CCL28,LIF,LIGHT and GRO in the observation group were significantly higher than those in the control group （P〈0.05）. The levels of CCL28 ,LIF,LIGHT and GRO in the observation group were high- er than those in the control group. The levels of CCL28, NAP-2 and MDC in the observation group were lower than those in the control group （P〈0.05）. Conclusion The regular detection of serum tumor markers spectrum and chemokine protein can predict the treatment prognosis and evaluate the Clinical curative effect.
出处
《重庆医学》
CAS
北大核心
2017年第25期3484-3485,3488,共3页
Chongqing medicine
基金
国家自然科学基金资助项目(81072034)
关键词
肺肿瘤
胃泌素释放肽
癌胚抗原
lung neoplasms
gastrin-releasing peptide
carcinoembryonic antigen
